Bell Potter Healthcare Conference 2026 Building the Future of TRPC-targeted Therapies 19 November 2026 ASX:NYR Authorised by Mr. John Moore, Non-Executive Chair, on behalf of the Board Important Notice and Disclaimer This presentation has been prepared by Nyrada Inc (“NYR” or “Company”). It...
Presentation - Bell Potter Healthcare Conference 2026
Filed with ASX · · 13 pages · English
Summary by 6ix AI
The presentation highlights the ongoing Phase IIa trial for Xolatryp in cardiac reperfusion injury, with updates on patient recruitment and safety assessments. Nyrada emphasizes the significant market opportunity for Xolatryp, particularly in the context of STEMI heart attacks, where current treatment options are limited. The company outlines multiple near-term catalysts for development and expansion of their clinical programs across various therapeutic areas.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Earlier from Nyrada
- Quotation of Attaching Options
- Update - Proposed issue of securities - NYR
- Quotation of New Options
- Notice of Initial Substantial Holding - J Moore
- Change of Director's Interest Notice - JM
Later from Nyrada
All Nyrada news releasesFollow Nyrada into a list and get an email when it puts out news.
Follow Nyrada